2017 American Transplant Congress
A Pilot Trial of Genotype-Guided Dosing versus Standard Clinical Dosing in Pediatric Solid Organ Transplants.
The Hospital for Sick Children, Toronto, ON, Canada
Purpose: Tacrolimus pharmacokinetics are influenced by age and variation in the CYP3A5 gene with CYP3A5 expressors (AA/AG) being fast metabolizers. The purpose of this trial…2017 American Transplant Congress
Prevalence of CYP3A Genomic Variances and Impact on Tacrolimus Dosing Requirements in Kidney Transplant Recipients in Eastern North Carolina.
1Vidant Medical Center, Greenville, NC; 2East Carolina University, Greenville, NC
BACKGROUND: African American (AA) patients are substantially more likely to express CYP3A5. Presence of CYP3A5 polymorphisms is an important pharmacotherapeutic consideration due to the extensive…2017 American Transplant Congress
Tacrolimus Pharmacogenomics: Association of Genetic Variants with Clinical Factors Including Tacrolimus Requirement, Clearance, Intraindividual Variability, and Coefficient Variation.
Background: Tacrolimus, which plays a backbone in immunosuppressive therapy, has a different effect in absorption according to intraindividual and interindividual variability, and it is a…2017 American Transplant Congress
Is Once-Daily Extended-Release Tacrolimus Better Than Twice-Daily Standard-Release Tacrolimus? A Meta-Analysis of Randomized Controlled Trials.
Tacrolimus is one of the major immunosuppressants commonly used in transplant recipients. Extended-release tacrolimus is expected to have immunosuppressant effects equivalent to standard-release tacrolimus while…2017 American Transplant Congress
Association with Tacrolimus Intraindividual Variability, Acute Microinflammation Based on 1 Year-Transplanted Kidney Biopsy After Transplantation, and Biopsy-Proven Acute Rejection.
Surgery, Seoul National University College of Medicine, Seoul, Korea
Background: The purpose of this study was to investigate relationship between tacrolimus intraindividual variability (IIV), acute microinflammation (AMI) based on 1 year-transplanted kidney biopsy, and…2017 American Transplant Congress
Impact of Antihypertensive (AHT) Choice and Advagraf® Dose on Interstitial Fibrosis/Tubular Atrophy (IF/TA) and IF/TA Progression in Renal Allografts 24 Months Post-Transplantation (Tx).
IF/TA may be delayed using ACEi- or ARB-type AHTs, which target the renin-angiotensin system (RAS), as well as by optimizing tacrolimus (TAC) exposure. The effect…2017 American Transplant Congress
Higher Tacrolimus Blood Levels Predict Better Graft Survival in Kidney Recipients with De Novo DSA.
Background: De novo anti-HLA donor specific antibodies (dnDSA) are associated with poorer outcomes in kidney transplant recipients. Nonetheless, their monitoring post transplant is not widespread,…2016 American Transplant Congress
Blockade of HLA Antibody-Triggered Classical Complement Activation by High-Affinity Humanized Monoclonal Anti-C1s Antibody TNT009 – Results of a First-in-Human Phase 1 Trial.
Study purpose: Classical complement may play a key role in ABMR. A promising therapeutic approach could be complement inhibition at the level of key component…2016 American Transplant Congress
Establishing the Relationship Between Receptor Occupancy, Serum Exposure and Pathway Inhibition by the Blocking, Non-Depleting Anti-CD40 Antibody CFZ533 to Inform Dose Selection in Clinical Transplantation.
Novartis Institutes for Biomedical Research, Basel, Switzerland.
Background. CD40-CD154 pathway blockade significantly prolongs renal allograft survival in non-human primates (NHPs), and trials of the novel blocking, non-depleting anti-CD40 monoclonal antibody (mAb) CFZ533…2016 American Transplant Congress
Advantages of Computerized Dosing Strategy in Tacrolimus Treatment of Renal Transplant Patients.
Purpose: Tacrolimus (Tac) is widely used in immunosuppression for kidney transplant (KT) patients. Despite this, it is still difficult for expert physicians to achieve and…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- Next Page »